BIOFRONTERA AG - DE000A4BGGM7 (Stock)
Düsseldorf
| Price | Diff.% | Date & Time | Bid volume | Bid | Ask | Ask volume |
|---|---|---|---|---|---|---|
2,30 EUR
|
-5,7377% | 17.04.2025 19:31 | - | - | - | - |
| Contact | |
|---|---|
|
|
Biofrontera AG Hemmelrather Weg 201 51377, Leverkusen, DE |
| Phone | +49-214-87-63-2-0 |
| Fax | +49-214-87-63-2-90 |
| info@biofrontera.com | |
| Internet | http://biofrontera.com |
| IR Contact/PR Contact | -/- |
| Symbol | DE0006046113EUR |
| End of financial year | 31.12.2025 |
| Issued capital | 13.976.782,60 EUR |
| Shareholders | |
|---|---|
| Freefloat | 91,41% |
| Biofrontera, Inc. | 8,58% |
| Arvernus Capital AG | 0,01% |
| Board | |
|---|---|
| María del Pilar de la Huerta Martínez | Member of Executive Committee |
| Dr. Helge Lubenow | Chairman of Supervisory Board |
| Hansjörg Plaggemars | Member of Supervisory Board |
| Dr. Heikki Lanckriet | Member of Supervisory Board |
| Karlheinz Schmelig | Member of Supervisory Board |
| Activity Description |
|---|
|
Biofrontera AG engages in the research, development, and marketing of dermatological products. Its products include Ameluz, BF-RhodolesXepi and Belixos. The company was founded by Hermann Lübbert in 1997 and is headquartered in Leverkusen, Germany. |
© 2000 - 2025 UniCredit Bank Austria AG. Please read our terms and conditions
Implemented and powered by FactSet
Fond data is provided from Mountain-View Data Gmbh
Austria-HomePage Version 2.0.54
